Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
NCT02742129 · View on ClinicalTrials.gov ↗
Study Summary
A randomized, double-blind, placebo-controlled crossover study to assess the effect of inorganic nitrite (NO2) on aerobic capacity (peak VO2) after four weeks of dosing. Approximately 100 participants will be enrolled in this 2\*2 crossover study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nebulized Sodium Nitrite
Study Locations (20)
Massachusetts
- Tufts Medical Center — Boston
- Massachusetts General Hospital — Boston
- Brigham and Women's Hospital — Boston
- Boston V.A. Healthcare System — West Roxbury
Missouri
- University of Missouri Health System — Columbia
- V.A St. Louis Health Care System — St Louis
- Washington University School of Medicine — St Louis
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
- Metro Health System — Cleveland
- Cleveland Clinic Foundation — Cleveland
Pennsylvania
- Abington Memorial Hospital — Abington
- University of Pennsylvania Health System — Philadelphia
- Jefferson Medical College — Philadelphia
Georgia
- Emory University School of Medicine — Atlanta
Illinois
- Northwestern University — Chicago
Maryland
- Johns Hopkins Hospital — Baltimore
Minnesota
- Mayo Clinic — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2017-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02742129
The ClinicalTrials.gov registry entry for NCT02742129 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Hernandez, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02742129 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Massachusetts, Missouri, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02742129 about?
NCT02742129 is a clinical study titled "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF". A randomized, double-blind, placebo-controlled crossover study to assess the effect of inorganic nitrite (NO2) on aerobic capacity (peak VO2) after four weeks of dosing. Approximately 100 participants will be enrolled in this 2\*2 crossover study.
What is the current status of trial NCT02742129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2016-08-10. Estimated completion is 2017-12-27.
What conditions does trial NCT02742129 study?
This clinical trial studies the following conditions: Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02742129?
The interventions under investigation include: Placebo (DRUG), Nebulized Sodium Nitrite (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02742129?
This trial is sponsored by Adrian Hernandez, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02742129 being conducted?
This trial has 20 study locations across Georgia, Illinois, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.